Telomir-Zn shows dose-dependent survival improvement in Wilson's disease model

Telomir Pharmaceuticals announced peer-reviewed publication of preclinical data demonstrating that Telomir-Zn produced dose-dependent survival improvements and reduced hepatic copper burden in a Wilson's disease model. The findings support the drug candidate's biological activity and potential therapeutic approach for this rare genetic disorder.